510(k) · Cleared
ClearedModification of Tricyclic Serum Tox Eia Assay
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Diagnostic Reagents, Inc. · LFH U.V. Spectrometry, Tricyclic Antidepressant Drugs
Cleared on Nov 18, 1998 after a 62-day review. FDA’s file for it is a 510(k) statement, which names no predicate. 2 later devices descend from it.
- Decided
- Nov 18, 1998
- Review
- 62 days
- Class
- Class II
- Product code
- LFH
- Recalls
- None
- Predicates
- 0
2 later devices descend from it, 1 citing it directly.
- This deviceK983268 Modification of Tricyclic Serum Tox Eia AssayDiagnostic Reagents, Inc. · 1998
- Descendant · cites it directly · 1 of its ownK213875 DRI TM Tricyclics Serum Tox AssayMicrogenics Corporation · 2022
- Descendant · 2 generations on · 0 of its ownK231020 Alinity c Tricyclic Antidepressants Reagent KitMicrogenics Corporation · 2023
Most influential descendants
Showing 2 of 2 · See allView FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| 0 (this device) | K983268 | Modification of Tricyclic Serum Tox Eia Assay | Diagnostic Reagents, Inc. | 1998 | — |
| +1 | K213875 | DRI TM Tricyclics Serum Tox Assay | Microgenics Corporation | 2022 | — |
| +2 | K231020 | Alinity c Tricyclic Antidepressants Reagent Kit | Microgenics Corporation | 2023 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2022 | 1 | 0 |
| 2023 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in LFH? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new LFH device
- #1 K213875 DRI TM Tricyclics Serum Tox Assayscore 7.6 · 1 generation · no Class I recall
- #2 Held for the reportin the report
What was it cleared against?
FDA’s file for it is a 510(k) statement, which names no predicate.
What descends from it? (2)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K213875 | DRI TM Tricyclics Serum Tox Assay | 2022 | 1 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- Of its descendants, K213875 (Microgenics Corporation, 2022) has gone furthest, with 1 descendant of its own.
How does its category compare?
All LFH devicesLFH U.V. Spectrometry, Tricyclic Antidepressant Drugs: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · LFH
1in 2023
2026 to Oct 25, outlined.
Median 510(k) review, days · LFH
Too few LFH 510(k)s in any year since 2007 to give a median.
Recalls per year · LFH
No recall names LFH since 2007.
Adverse event reports per year · LFH
1in 2007
MAUDE reports naming product code LFH, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 1 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 0 | — | 0 | 0 |
| 2017 | 0 | — | 0 | 0 |
| 2018 | 0 | — | 0 | 0 |
| 2019 | 0 | — | 0 | 0 |
| 2020 | 0 | — | 0 | 0 |
| 2021 | 0 | — | 0 | 0 |
| 2022 | 1 | — | 0 | 0 |
| 2023 | 1 | — | 0 | 0 |
| 2024 | 0 | — | 0 | 0 |
| 2025 | 0 | — | 0 | 0 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
This homogeneous tricyclics serum tox enzyme immunoassay is intended to be used for qualitative and semiquantitative determination of tricyclic antidepressants in serum, plasma or urine of patients suspected of drug overdose. A 300 ng/mL nortriptyline cutoff calibrator is used in this assay to differentiate a positive from a negative sample. Detection of the drug presence and its approximate concentration in serum, plasma or urine from patients suspected of drug overdose can assist the physician in diagnosis and determination of steps towards treatment.
Indications for use read by OCR from a scanned FDA 510(k) statement, so letters may be misread. Check the PDF before quoting it.
https://510kreport.com/device/K983268 · printed Nov 4, 2026
Cite this page
510(k) Report. “K983268: Modification of Tricyclic Serum Tox Eia Assay.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K983268
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026